



Image

1617

CERTIFICATE OF MAILING
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

February 5, 2004
Date


Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe Sophia Ran and
Rolf A. Brekken (As Amended)

Group Art Unit: 1617

Serial No.: 09/351,149

Examiner: Sharareh, S.

Filed: July 12, 1999

Atty. Dkt. No.: 3999.002383

For: CANCER TREATMENT KITS
COMPRISING THERAPEUTIC
CONJUGATES THAT BIND TO
AMINOPHOSPHOLIPIDS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22131-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A Final Official Action has been received in the present application. However, this Supplemental Information Disclosure Statement is being submitted in an abundance of caution and should be enterable under 37 C.F.R. § 1.97(d) in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent office in a counterpart foreign application of the present case. The listed documents were cited in an Official Action on the merits in a co-pending application of one of the present inventors, Serial No. 10/376,194 (Attorney Docket No. 3999.000597), mailed from the P.T.O. on January 13, 2004, less than three months before the filing of the present statement, and evidently could not have been submitted before receipt.

Should any fees under 37 C.F.R. §§ 1.97(d) and 1.17(p) be due, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/3999.002383.

Respectfully submitted,

Williams, Morgan & Amerson, P.C.
Customer No. 23720



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4079

Date: February 5, 2004

Form PTO-1449 (modified)

Atty. Docket No.
3999.002383Serial No.
09/351,149

Office of Patents and Publications for Applicant's

Applicant
Thorpe, Ran and Brekken

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
July 12, 1999Group:
1617U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page*Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A31	5,057,313	October 15, 1991	Shih <i>et al.</i>	424	85.91	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C100	Hardman <i>et al.</i> , In Goodman & Gilman's The Pharmacological Basis of Therapeutics Ninth Edition, pages 51 and 57-58, 1996.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.